What is Wedbush’s Forecast for PRAX Q3 Earnings?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Investment analysts at Wedbush reduced their Q3 2025 earnings estimates for shares of Praxis Precision Medicines in a research report issued to clients and investors on Monday, August 4th. Wedbush analyst L. Chico now expects that the company will post earnings of ($3.23) per share for the quarter, down from their previous estimate of ($2.87). Wedbush currently has a “Underperform” rating and a $28.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. Wedbush also issued estimates for Praxis Precision Medicines’ Q4 2025 earnings at ($3.24) EPS, FY2025 earnings at ($13.08) EPS, Q1 2026 earnings at ($2.00) EPS, Q2 2026 earnings at ($2.04) EPS, Q3 2026 earnings at ($2.08) EPS, Q4 2026 earnings at ($2.13) EPS, FY2026 earnings at ($8.25) EPS, FY2027 earnings at ($6.96) EPS, FY2028 earnings at ($5.54) EPS and FY2029 earnings at ($3.93) EPS.

Several other equities analysts have also issued reports on PRAX. Chardan Capital reissued a “buy” rating and set a $80.00 target price on shares of Praxis Precision Medicines in a research note on Tuesday, July 29th. Oppenheimer lifted their target price on Praxis Precision Medicines from $97.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. HC Wainwright restated a “buy” rating and set a $115.00 target price (up from $105.00) on shares of Praxis Precision Medicines in a research note on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $80.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Praxis Precision Medicines currently has an average rating of “Moderate Buy” and an average target price of $95.22.

Praxis Precision Medicines Stock Performance

NASDAQ:PRAX opened at $48.60 on Wednesday. The stock has a market capitalization of $1.02 billion, a P/E ratio of -3.95 and a beta of 2.62. Praxis Precision Medicines has a fifty-two week low of $26.70 and a fifty-two week high of $91.83. The company has a 50 day moving average price of $47.79 and a 200 day moving average price of $48.66.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Monday, August 4th. The company reported ($3.31) EPS for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.09. Praxis Precision Medicines had a negative return on equity of 60.07% and a negative net margin of 2,137.48%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Praxis Precision Medicines by 2.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,135 shares of the company’s stock valued at $856,000 after acquiring an additional 258 shares during the last quarter. California State Teachers Retirement System boosted its position in Praxis Precision Medicines by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 12,726 shares of the company’s stock worth $979,000 after acquiring an additional 275 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Praxis Precision Medicines by 88.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 629 shares of the company’s stock valued at $26,000 after acquiring an additional 295 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Praxis Precision Medicines in the fourth quarter valued at $30,000. Finally, MetLife Investment Management LLC lifted its position in Praxis Precision Medicines by 5.4% during the fourth quarter. MetLife Investment Management LLC now owns 10,675 shares of the company’s stock worth $822,000 after buying an additional 544 shares during the period. 67.84% of the stock is owned by hedge funds and other institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.